Amgen (NASDAQ:AMGN) is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares.

Big drug companies such as Amgen, AbbVie (NYSE:ABBV), and Johnson & Johnson (NYSE:JNJ) offer investors predictable dividend-friendly revenue regardless of the economy's whims and whispers. But investors are correct to wonder whether Amgen's dividend can be sustained in light of billions in at-risk revenue tied to the future patent expiration of top-selling drugs.

In the following slideshow you'll see whether I think Amgen's dividend is safe and gain insight into how Amgen's dividend payout matches up with industry peers AbbVie and Johnson & Johnson.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.